Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to $23.8 million.

  • Day One Biopharmaceuticals' Non-Current Assets rose 20.18% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 20.18%. This contributed to the annual value of $20.5 million for FY2024, which is 2543.15% up from last year.
  • Day One Biopharmaceuticals' Non-Current Assets amounted to $23.8 million in Q3 2025, which was down 3.25% from $24.6 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Non-Current Assets' 5-year high stood at $25.7 million during Q1 2025, with a 5-year trough of $611,000 in Q1 2024.
  • In the last 3 years, Day One Biopharmaceuticals' Non-Current Assets had a median value of $18.5 million in 2024 and averaged $13.5 million.
  • In the last 5 years, Day One Biopharmaceuticals' Non-Current Assets tumbled by 34.85% in 2023 and then spiked by 4,107.04% in 2025.
  • Day One Biopharmaceuticals' Non-Current Assets (Quarterly) stood at $1.2 million in 2022, then plummeted by 34.85% to $774,000 in 2023, then skyrocketed by 2,543.15% to $20.5 million in 2024, then rose by 20.18% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q3 2025, $24.6 million for Q2 2025, and $25.7 million during Q1 2025.